Feasibility Study of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UC-MSC) in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Cord blood stem cell therapy (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Translational Biosciences
- 19 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2018 Status changed from active, no longer recruiting to recruiting.
- 10 Sep 2018 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.